Souhaitez-vous accéder aux communiqués récents ?

  This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ...

Hexvix blue-light flexible cystoscopy allows for better identification and management of recurrent low-grade tumors in the outpatient setting, providing clinical, patient, and economic benefits....

Oslo, Norway, 2 March 2015: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to announce that the National...

Oslo, Norway, 12 February 2015: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for fourth...

Photocure will present its fourth quarter and full year report 2014 on Thursday 12 February 2015 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives...

In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light ...

Cevira® advances towards Phase 3 for treatment in patients with cervical high grade lesions (HSIL) Oslo, Norway, 7 January 2015: Photocure ASA (OSE:PHO), a specialty pharmaceutical company focused...

Kjetil Hestdal, President and CEO of Photocure, has today, December 23th 2014, exercised 37 500 share options in Photocure ASA, at the strike price of NOK 18.30. After the transaction, Kjetil...

Oslo, Norway, 22th December 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, provides an update on business...

Oslo, Norway, 6 November 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for third...